TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02529930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.16 Immunotherapy (DNA vaccine)
Description: Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.16 Immunotherapy (DNA vaccine)
Description: Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
Study: NCT00714974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS
Description: Sedation dosing based on BIS value, oer treating physician discretion.
Study: NCT02571556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
Description: Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
Study: NCT03923153

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training with PowerBreathe (IMT Technologies Ltd., Birmingham,England)
Description: Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham group with PowerBreathe (IMT Technologies Ltd., Birmingham, England)
Description: Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 10% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department.
Study: NCT01691378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Window to Hope
Description: Psychotherapy - Group
Study: NCT04110353

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressings: Prevena dressings
Description: Prevena dressing to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressings: ciVAC dressings
Description: Closed incision VAC dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
Study: NCT01510080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted live supervision
Description: 8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed video-based supervision
Description: 12 video-based sessions (each 50 minutes) during treatment of 2 patients
Study: NCT03236584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine plus adefovir combination
Description: continuing lamivudine plus adefovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: switching to tenofovir
Study: NCT01541384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitality GlowCaps
Description: The main research instrument is an electronic pill bottle called GlowCaps that has the ability to transmit reminder messages via email, text, and phone to the subject, and adherence data to special servers. The messages will be sent twice a day, if a subject misses a dose of their immunosuppression medication (tacrolimus). Each time the pill bottle is opened (or not opened), a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network. No extra cellular or wireless service is required from subjects for the GlowCap to function.~Note: GlowCaps are a Class 1 Medical Device registered with the FDA. Because of this Class 1 designation, they are not subject to FDA testing or approval.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitality GlowCaps
Description: The main research instrument is an electronic pill bottle called GlowCaps that has the ability to transmit reminder messages via email, text, and phone to the subject, and adherence data to special servers. The messages will be sent twice a day, if a subject misses a dose of their immunosuppression medication (tacrolimus). Each time the pill bottle is opened (or not opened), a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network. No extra cellular or wireless service is required from subjects for the GlowCap to function.~Note: GlowCaps are a Class 1 Medical Device registered with the FDA. Because of this Class 1 designation, they are not subject to FDA testing or approval.

Intervention type: DEVICE
Group type: OTHER
Intervention: Vitality GlowCaps
Description: The main research instrument is an electronic pill bottle called GlowCaps that has the ability to transmit reminder messages via email, text, and phone to the subject, and adherence data to special servers. The messages will be sent twice a day, if a subject misses a dose of their immunosuppression medication (tacrolimus). Each time the pill bottle is opened (or not opened), a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network. No extra cellular or wireless service is required from subjects for the GlowCap to function.~Note: GlowCaps are a Class 1 Medical Device registered with the FDA. Because of this Class 1 designation, they are not subject to FDA testing or approval.
Study: NCT05215964

Intervention type: PROCEDURE
Intervention: Renal artery embolization
Description: After catheterization of renal arteries, multiple coils are applied to embolize renal arteries until blood flow stasis
Study: NCT03203330

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TG-C
Description: 2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: 2 mL normal saline injection
Study: NCT05293977

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine care by the dispensing pharmacist
Description: Patients in the control group received routine care by the dispensing pharmacist and seen by research assistant for data collection only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical education/counseling about prescribed antibiotic
Description: Patient in the intervention group was provided with pharmaceutical education about his/her prescribed antibiotic by the trained clinical pharmacist. To prepare the education about antibiotics, the 10 most commonly prescribed antibiotics were determined in advance from hospital records: Amoxicillin or Amoxicillin/Clavulanic acid, Ciprofloxacin, Levofloxacin, Azithromycin, Cefuroxime, Cephalexin, Clindamycin, Doxycycline, Metronidazole, Trimethoprim/Sulfamethoxazole. Standard education points about antibiotics include (i) mechanism of action and/or use, (ii) correct administration method, (iii) correct timing, (iv) possible adverse effect and self-management intervention methods when faced with side effects, (v) what to do in case of missing any dose.
Study: NCT00565773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept will be given within 24 hours of transplantation via a peripheral intravenous catheter at a dose of 10mg/kg (actual body weight) infused over 30 mins. The dose will be repeated on study days 4 (post op day 3) and 8 (post op day 7), then every 2 weeks for 5 additional doses. Thereafter, belatacept will be given once every 4 weeks (+/- 3 days) at 10mg/kg through 6 months then at 5mg/kg indefinitely.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be started on postoperative day 1 at a dose of 2 mg per day orally. Doses will be adjusted to maintain 24-hour trough levels of 8-10ng/ml until the drug is weaned. Toxicity attributable to sirolimus (e.g., mouth ulcers, arthralgias) will prompt dose reduction to address clinical concerns in this regard. If sirolimus trough levels need to be reduced below 4ng/ml to control drug side effects, the patient will be considered intolerant to the drug and will be changed to other medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: All participants will receive a single dose of 30 mgs of alemtuzumab on the day of transplantation.
Study: NCT04562766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: 400mg Caplet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg Caplet
Study: NCT01691378

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
Study: NCT00417664

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Dexmedetomidine administered as part of anesthesia in cardiac surgery patients

Intervention type: DRUG
Intervention: Propofol
Description: Propofol administered as part of anesthesia in cardiac surgery patients

Intervention type: DRUG
Intervention: Midazolam
Description: Midazolam administered as part of anesthesia in cardiac surgery patients
Study: NCT05739487

Intervention type: PROCEDURE
Intervention: selective intra-arterial thrombolysis
Description: IAT introduces rt-PA (50mg) directly into the ophthalmic circulation by super-selective microcatheterization
Study: NCT03177148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention by Clinicians
Description: •Parents will complete surveys after enrollment and at the end of intervention and participate in intervention visits by pediatric clinicians and telephonic counseling with Registered Dietitians (RDs).~Intervention by pediatric clinicians: up to 4 sessions of MI, in-person Intervention by RDs: up to 6 sessions of MI via telephone.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Pediatric clinicians provide care as normal
Study: NCT05199792

Intervention type: DIAGNOSTIC_TEST
Intervention: Dotarem
Description: (Dotarem) (0.4 ml/kg (0.2 mmol/kg))
Study: NCT00931632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nitrogen gas will be administered in the same manner as the experimental drug.
Study: NCT01001312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daxor Blood Volume Analysis
Description: Radiolabeled albumin for direct measurement of blood volume

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical volume status assessment
Description: Volume assessment based on history and physical examination
Study: NCT03334357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-EMS
Study: NCT01351818

Intervention type: DRUG
Intervention: Growth Hormone
Study: NCT01904890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRC Prevention and Screening Education
Description: Refer to Arm Description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: Refer to Arm Description
Study: NCT02209363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auto-adjusting positive airway pressure
Description: nightly use for 6 months

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Nasal dilator strips
Description: nightly use for 6 months
Study: NCT03898193

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast
Description: Montelukast, 5 mg Chewable Tablets, manufactured by Pharmtechnology LLC, Republic of Belarus

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast
Description: Montelukast, 5 mg Chewable Tablets, manufactured by Pharmtechnology LLC, Republic of Belarus

Intervention type: DRUG
Group type: OTHER
Intervention: Singulair
Description: Singulair, 5 mg Chewable Tablets, marketed by Merck Sharp \& Dohme B.V., the Netherlands

Intervention type: DRUG
Group type: OTHER
Intervention: Singulair
Description: Singulair, 5 mg Chewable Tablets, marketed by Merck Sharp \& Dohme B.V., the Netherlands
Study: NCT02471573

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-all protocol
Description: Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh transfer protocol
Description: Two embryos are selected and transferred fresh in the same cycle.
Study: NCT02151617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: 40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: To be decided dose, tablet once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet one time once without a meal, followed by once daily dosing for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: Tablet, to be decided dose, once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, once daily, 14 days
Study: NCT04022330

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: The blood sampling will be done just before surgery
Study: NCT00053209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study: NCT02758847

Intervention type: DEVICE
Group type: OTHER
Intervention: Angiogram, Medtronic DCB (paclitaxel)/stent
Description: Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Each participant will receive angiogram with DCB (drug coated balloon)/stenting with wound debridement. 50% of subjects will receive an Angiogram, Medtronic DCB (paclitaxel)/stent. Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.

Intervention type: DEVICE
Group type: OTHER
Intervention: Angiogram, Bard DCB (paclitaxel)/stent
Description: Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. 50% of subjects will receive 'Angiogram, Bard DCB (paclitaxel)/stent' . Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
Study: NCT02937480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-specific training
Description: The task-specific training will be composed by 30 minutes for upper limb and 30 minutes for lower limb tasks. Subjects will performed five minutes of exercise in each station of the circuit and only the last station will last 10 minutes and will involve a walking training with auditory stimulation. Individuals will be encouraged to work as hard as possible at each station and verbal feedback and instructions aimed at improving performance will be taken. Between each task, the participants will be allowed to rest for at least 1-2 minutes, and individual adjustments will be carried out for better adaptations to the training.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Global stretching, memory exercises, health care orientation
Description: The control intervention will be composed by 40 minutes for global stretching, 20 minutes of memory exercises and health care orientation
Study: NCT02894333

Intervention type: BEHAVIORAL
Intervention: behavioral observation
Study: NCT04321902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)
Study: NCT01328964

Intervention type: DRUG
Intervention: Fluticasone propionate
Description: fluticasone propionate 44 mcg

Intervention type: DRUG
Intervention: Budesonide
Description: budesonide

Intervention type: DRUG
Intervention: Montelukast
Description: montelukast
Study: NCT04221919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β -Blockers
Description: Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β -Blockers
Description: Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β -Blockers
Description: Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β -Blockers
Description: Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate
Study: NCT03528551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turoctocog alfa pegol
Description: Turoctocog alfa pegol 75 IU/kg body weight will be administered once weekly as intravenous injections for a duration of 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turoctocog alfa pegol
Description: Turoctocog alfa pegol 60 IU/kg body weight (for patients younger than 12 years) and 50 IU/kg body weight (for patients, 12 years or older) will be administered twice weekly as intravenous injections for a duration of 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turoctocog alfa pegol
Description: Turoctocog alfa pegol 50 IU/kg body weight will be administered three times weekly as intravenous injections for a duration of 2 years.
Study: NCT02915224

Intervention type: DRUG
Intervention: Chlorambucil
Description: Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.

Intervention type: DRUG
Intervention: Obinutuzumab
Description: Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
Study: NCT02701621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRT-AT
Description: Aquatic therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MIRT
Description: Land-based Therapy
Study: NCT01494805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV.sFlt-1
Description: 1 x 10\^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV.sFlt-1
Description: 1 x 10\^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (ranibizumab alone)
Description: Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).
Study: NCT02590055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/docetaxel combination
Study: NCT03280459

Intervention type: PROCEDURE
Intervention: robot-assisted cystectomy
Description: Removal of urinary bladder in oncologic or functional setting using a assistance of a operation robotic for laparoscopy

Intervention type: PROCEDURE
Intervention: robot-assisted cystectomy
Description: Removal of urinary bladder in oncologic or functional setting using a assistance of a operation robotic for laparoscopy